Data / Drug companies / Estradiol
Estradiol: 53 companies and 250 products in the FDA NDC directory
Estradiol is listed in the FDA National Drug Code Directory by 53 companies, with 250 products in commercial distribution. 199 of the products (79.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; patch; patch, extended release, and the newest product started marketing on May 13, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 53
- Products
- 250
- Generic (ANDA) products
- 199 (79.6%)
- Application numbers
- 35
- Routes
- Transdermal, Oral, Topical, Vaginal
- Brand names
- Dotti, Climara, Vivelle-Dot, Divigel, Lyllana, Minivelle, Estrace, Menostar
- openFDA record search
- api.fda.gov
Companies that list estradiol
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 21 | tablet; patch | Generic drugs (ANDA) | July 10, 2024 |
| Mylan Pharmaceuticals Inc. | 17 | patch; cream | Generic drugs (ANDA) | November 1, 2018 |
| Zydus Lifesciences Limited | 12 | patch; patch, extended release | Generic drugs (ANDA) | November 2, 2023 |
| Amneal Pharmaceuticals LLC | 11 | patch, extended release; tablet | Generic drugs (ANDA) | September 30, 2020 |
| Sandoz Inc | 11 | patch; patch, extended release | Authorized generics (NDA) | December 22, 2014 |
| Amneal Pharmaceuticals NY LLC | 10 | patch, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Bryant Ranch Prepack | 10 | patch, extended release; gel | Generic drugs (ANDA) | December 7, 2023 |
| Noven Therapeutics, LLC | 10 | film, extended release | Authorized generics (NDA) | January 1, 2018 |
| Ani Pharmaceuticals, Inc. | 9 | gel; tablet | Generic drugs (ANDA) | October 23, 2024 |
| Bryant Ranch Prepack | 9 | tablet; cream | Generic drugs (ANDA) | September 6, 2023 |
| NorthStar RxLLC | 9 | gel; tablet | Generic drugs (ANDA) | September 1, 2025 |
| Bayer HealthCare Pharmaceuticals Inc. | 7 | patch | New drug applications (NDA) | January 3, 2008 |
| Encube Ethicals, Inc. | 7 | gel; cream | Generic drugs (ANDA) | May 13, 2026 |
| NuCare Pharmaceuticals,Inc. | 7 | tablet; cream | Generic drugs (ANDA) | September 6, 2023 |
| Zydus Pharmaceuticals USA Inc. | 7 | patch | Generic drugs (ANDA) | November 2, 2023 |
| Asclemed USA, Inc. | 6 | tablet | Generic drugs (ANDA) | April 10, 2017 |
| Bryant Ranch Prepack | 6 | insert; tablet | Generic drugs (ANDA) | January 6, 2021 |
| Padagis Israel Pharmaceuticals Ltd | 6 | gel; cream | Generic drugs (ANDA) | December 7, 2023 |
| Remedyrepack Inc. | 5 | tablet | Generic drugs (ANDA) | November 22, 2023 |
| Sandoz Inc | 5 | patch, extended release | New drug applications (NDA) | January 8, 1999 |
| Trigen Laboratories, LLC | 5 | gel | New drug applications (NDA) | October 10, 2022 |
| Vertical Pharmaceuticals, LLC | 5 | gel | New drug applications (NDA) | December 17, 2019 |
| Zydus Pharmaceuticals USA Inc. | 5 | patch, extended release | Generic drugs (ANDA) | April 13, 2023 |
| Direct_Rx | 3 | tablet | Generic drugs (ANDA) | January 8, 2026 |
| Epic Pharma, LLC | 3 | tablet | Generic drugs (ANDA) | April 10, 2017 |
| Northwind Health Company, LLC | 3 | tablet | Generic drugs (ANDA) | February 15, 2023 |
| PD-Rx Pharmaceuticals, Inc. | 3 | tablet | Generic drugs (ANDA) | September 6, 2023 |
| Preferred Pharmaceuticals Inc. | 3 | tablet | Generic drugs (ANDA) | April 11, 2025 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 3 | tablet | Generic drugs (ANDA) | September 10, 2021 |
| Redpharm Drug | 3 | cream; tablet | Generic drugs (ANDA) | August 14, 2025 |
| Teva Pharmaceuticals USA, Inc. | 3 | tablet | Generic drugs (ANDA) | October 28, 1997 |
| AvKARE | 2 | tablet; cream | Generic drugs (ANDA) | February 16, 2021 |
| Northwind Health Company, LLC | 2 | tablet | Generic drugs (ANDA) | January 18, 2024 |
| PharmPak, Inc. | 2 | tablet | Generic drugs (ANDA) | July 9, 2019 |
| Teva Pharmaceuticals USA, Inc. | 2 | insert; cream | Generic drugs (ANDA) | January 2, 2018 |
| Allergan, Inc. | 1 | cream | Generic drugs (ANDA) | July 1, 2001 |
| Alvogen Inc. | 1 | cream | Generic drugs (ANDA) | March 5, 2018 |
| American Health Packaging | 1 | tablet | Generic drugs (ANDA) | May 2, 2025 |
| Amneal Pharmaceuticals of New York LLC | 1 | insert | Generic drugs (ANDA) | June 7, 2015 |
| Ascend Therapeutics US, LLC | 1 | gel, metered | New drug applications (NDA) | February 9, 2004 |
| Aurobindo Pharma Limited | 1 | tablet, film coated | Generic drugs (ANDA) | August 2, 2024 |
| Coupler LLC | 1 | tablet | Generic drugs (ANDA) | June 17, 2025 |
| Glenmark Pharmaceuticals Inc., USA | 1 | tablet, film coated | Generic drugs (ANDA) | September 17, 2018 |
| Novo Nordisk | 1 | insert | New drug applications (NDA) | January 11, 2010 |
| Nutritional Specialties, Inc. | 1 | spray | Unapproved homeopathic products | July 25, 2023 |
| Padagis US LLC | 1 | spray | New drug applications (NDA) | April 11, 2015 |
| Pfizer Laboratories Div Pfizer Inc | 1 | system | New drug applications (NDA) | June 5, 2023 |
| Prasco Laboratories | 1 | cream | Generic drugs (ANDA) | October 1, 2021 |
| Professional Complementary Health Formulas | 1 | liquid | Unapproved homeopathic products | August 15, 1984 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | October 28, 1997 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | September 6, 2023 |
| Solaris Pharma Corporation | 1 | gel | Generic drugs (ANDA) | January 28, 2026 |
| Viatris Specialty LLC | 1 | gel, metered | New drug applications (NDA) | June 2, 2014 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 74 | 29.6% |
| Patch | 49 | 19.6% |
| Patch, extended release | 45 | 18% |
| Gel | 36 | 14.4% |
| Cream | 20 | 8% |
| Film, extended release | 11 | 4.4% |
| Insert | 5 | 2% |
| Tablet, film coated | 3 | 1.2% |
| Gel, metered | 3 | 1.2% |
| Spray | 2 | 0.8% |
| System | 1 | 0.4% |
| Liquid | 1 | 0.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 199 | 79.6% |
| New drug applications (NDA) | 32 | 12.8% |
| Authorized generics (NDA) | 17 | 6.8% |
| Unapproved homeopathic products | 2 | 0.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Estrogen | 250 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.